Prophylaxis for Recurrent UTIs in Women
For women with recurrent UTIs, prioritize non-antibiotic prophylaxis first—specifically vaginal estrogen in postmenopausal women, methenamine hippurate, or immunoactive prophylaxis—reserving continuous or postcoital antibiotic prophylaxis only when non-antimicrobial strategies fail. 1, 2
Stepwise Prophylactic Approach
First-Line Non-Antibiotic Strategies
Postmenopausal women should receive vaginal estrogen replacement as first-line prophylaxis (strong recommendation). 2 This addresses the underlying pathophysiology of urogenital atrophy that predisposes to recurrent infections and has demonstrated efficacy without contributing to antimicrobial resistance. 2
Methenamine hippurate (1,000 mg twice daily) is strongly recommended for women without urinary tract abnormalities. 2 A 2022 randomized non-inferiority trial demonstrated that methenamine hippurate resulted in 1.38 UTI episodes per person-year compared to 0.89 with antibiotic prophylaxis, meeting the predefined non-inferiority margin of one additional episode per year—a difference most patients find acceptable given antibiotic stewardship concerns. 3
Immunoactive prophylaxis (OM-89) is strongly recommended across all age groups to reduce recurrent UTI frequency. 2 This represents a paradigm shift toward immune modulation rather than antimicrobial suppression. 1
Additional Non-Antibiotic Options (Weaker Evidence)
Premenopausal women should increase fluid intake, though evidence supporting this is limited. 2
Probiotics containing strains with proven efficacy for vaginal flora regeneration can be advised, but the recommendation strength is weak. 2
Cranberry products may reduce recurrent UTI episodes, but patients must be informed that evidence quality is low with contradictory findings. 2
D-mannose may reduce recurrent UTI episodes, though patients should understand the evidence is weak and contradictory. 2
Endovesical instillations of hyaluronic acid or hyaluronic acid/chondroitin sulfate combinations can be considered when less invasive approaches fail, though further confirmatory studies are needed. 2
Second-Line: Antibiotic Prophylaxis
Reserve continuous or postcoital antimicrobial prophylaxis for when non-antimicrobial interventions have failed, with thorough counseling about side effects and resistance risks. 2 The 2025 AUA/CUA/SUFU guidelines emphasize this represents a paradigm shift away from reflexive antibiotic use toward individualized risk-benefit assessment. 1
Antibiotic Prophylaxis Regimens (when indicated):
- Nitrofurantoin: 50-100 mg daily or 100 mg postcoitally 4
- Trimethoprim-sulfamethoxazole (Bactrim): 40/200 mg daily or 80/400 mg postcoitally 4
- Trimethoprim alone: 100 mg daily 5
Important caveat: Trimethoprim prophylaxis significantly increases breakthrough infections with trimethoprim-resistant organisms (71.4% of breakthrough infections in one study), whereas methenamine hippurate maintains low resistance rates (2.7%). 5 This ecological consideration strongly favors non-antibiotic approaches. 1
Self-Directed Treatment Option
For patients with good compliance, self-administered short-term antimicrobial therapy at symptom onset should be considered (strong recommendation). 2 This allows women to self-diagnose and initiate treatment without requiring prophylactic antibiotics, reducing overall antimicrobial exposure. 6
Diagnostic Confirmation
Diagnose recurrent UTI via urine culture (strong recommendation). 2 The 2025 AUA/CUA/SUFU guidelines emphasize that proper diagnosis requires acute-onset urinary symptoms plus pyuria (>5 WBC/high power field) plus significant bacteriuria. 1
Do not perform extensive routine workup (cystoscopy, full abdominal ultrasound) in women younger than 40 years with recurrent UTI and no risk factors. 2
Critical Pitfalls
Avoid treating asymptomatic bacteriuria—without acute symptoms, any degree of bacteriuria should not be treated as it represents colonization, not infection. 1
Recognize that adherence to non-antibiotic prophylaxis is poor (37% in one study), so inquire about actual adherence before escalating to antibiotic prophylaxis. 7 Vaginal estrogen had the highest prescription rate (81.1%) but still suffered from poor adherence. 7
The 2025 guidelines represent a fundamental shift: moving from microbial detection-driven treatment to clinician judgment weighing individual risks and benefits, prioritizing antibiotic stewardship and minimizing collateral damage from repetitive antimicrobial use. 1